For USA: Elecsys Estradiol III Assay

English

System information
For cobas e 411 analyzer: test number 1370
For MODULAR ANALYTICS E170, cobas e 601 and cobas e 602 analyzers:
Application Code Number 223

Intended use
Immunooassay for the in vitro quantitative determination of estradiol in human serum and plasma.

The electrochemiluminescence immunooassay "ECLIA" is intended for use on Elecsys and cobas e immunoassay analyzers.

Note:
Please note that the catalogue number appearing on the package insert retains only the first 8 digits of the 11-digit Catalogue number: 06656021190 for the Estradiol III. The last 3 digits -190 have been replaced by -119 for logistic purposes.

Summary
Estrogens are responsible for the development of the secondary female sex characteristics. Together with gestagens they control all the important female reproductive processes.

The biologically most active estrogen is 17ß-estradiol. This is a steroid hormone having a molecular weight of 272 daltons.

Estrogens are produced primarily in the ovary (follicle, corpus luteum), but small quantities are also formed in the testes and in the adrenal cortex.

During pregnancy, estrogens are mainly formed in the placenta. About 98% of estradiol is bound to transport proteins (SHBG = sex hormone binding globulin).1

Estrogen secretion is biphasic during the menstrual cycle. The determination of estradiol is utilized clinically in the elucidation of fertility disorders in the hypothalamus-pituitary-gonadal axis, gynecomasia, estrogen-producing ovarian and testicular tumors and in hyperplasia of the adrenal cortex. Further clinical indications are the monitoring of fertility therapy and determining the time of ovulation within the framework of in vitro fertilization (IVF).2,3,4

The Elecsys Estradiol III assay employs a competitive test principle using two monoclonal antibodies specifically directed against 17ß-estradiol. Endogenous estradiol released from the sample by mesterolone competes with the added estradiol derivative labeled with a ruthenium complex5 for the binding sites on the biotinylated antibody.

a) Tris(2,2′-bipyridyl)ruthenium(II)-complex(Ru(bpy)2+)5

Test principle
Competition principle. Total duration of assay: 18 minutes.

1st incubation: By incubating the sample (25 mL) with two estradiol-specific biotinylated antibodies, immunocomplexes are formed, the amount of which is dependent upon the analyte concentration in the sample.

2nd incubation: After addition of streptavidin-coated microparticles and an estradiol derivative labeled with a ruthenium complex, the still-vacant sites of the biotinylated antibodies become occupied, with formation of an antibody-hapten complex. The entire complex becomes bound to the solid phase via interaction of biotin and streptavidin.

The reaction mixture is aspirated into the measuring cell where the microparticles are magnetically captured onto the surface of the electrode. Unbound substances are then removed with ProCell/ProCell M. Application of a voltage to the electrode then induces chemiluminescent emission which is measured by a photomultiplier.

- Results are determined via a calibration curve which is instrument-specifically generated by 2-point calibration and a master curve provided via the reagent barcode or e-barcode.

Reagents – working solutions
The reagent rackpack is labeled as E2 III.

M Streptavidin-coated microparticles (transparent cap), 1 bottle, 6.5 mL:
Streptavidin-coated microparticles 0.72 mg/mL; preservative.

R1 Anti-estradiol-Ab-biotin (gray cap), 1 bottle, 9 mL:
Two biotinylated monoclonal anti-estradiol antibodies (rabbit)
2.5 ng/mL and 4.5 ng/mL; mesterolone 130 ng/mL; MES buffer 50 mmol/L, pH 6.0; preservative.

R2 Estradiol-derivative=Ru(bpy)2+ (black cap), 1 bottle, 9 mL:
Estradiol derivative, labeled with ruthenium complex 4.5 ng/mL; MES buffer 50 mmol/L, pH 6.0; preservative.

b) MES = 2-morpholino-ethane sulfonic acid

Precautions and warnings
For in vitro diagnostic use.

Exercise the normal precautions required for handling all laboratory reagents. Disposal of all waste material should be in accordance with local guidelines.

Safety data sheet available for professional user on request.

For USA: For prescription use only.

Avoid foam formation in all reagents and sample types (specimens, calibrators and controls).

Reagent handling
The reagents in the kit have been assembled into a ready-for-use unit that cannot be separated.

All information required for correct operation is read in from the respective reagent barcodes.

Storage and stability
Store at 2-8 °C. Do not freeze.

Store the Elecsys reagent kit upright in order to ensure complete availability of the microparticles during automatic mixing prior to use.

Stability:

unopened at 2-8 °C up to the stated expiration date
after opening at 2-8 °C 12 weeks
on the analyzers 8 weeks

Specimen collection and preparation
Only the specimens listed below were tested and found acceptable.

Serum collected using standard sampling tubes or tubes containing separating gel.

Li-heparin, K$_2$-EDTA and K$_3$-EDTA plasma as well as plasma separation tubes.

Criterion: Slope 0.9-1.1 + intercept within ± 10 pg/mL + coefficient of correlation ≥ 0.95.

For individual samples recovery within 70-130 % of serum value > 100 pg/mL, recovery of ± 20 pg/mL of serum value ≤ 100 pg/mL. Stable for 12 hours at 20-25 °C, 2 days at 2-8 °C, 6 months at -20 °C. Freeze only once.

The sample types listed were tested with a selection of sample collection tubes that were commercially available at the time of testing, i.e. not all available tubes of all manufacturers were tested. Sample collection systems from various manufacturers may contain differing materials which could affect the test results in some cases. When processing samples in primary tubes...
Estradiol III

(sampling collection systems), follow the instructions of the tube manufacturer.
Centrifuge samples containing precipitates and frozen samples before performing the assay.
Do not use heat-inactivated samples.
Do not use samples and controls stabilized with azide.
Ensure the samples, calibrators and controls are at 20-25 °C prior to measurement.
Due to possible evaporation effects, samples, calibrators and controls on the analyzers should be analyzed/measured within 2 hours.

Materials provided
See "Reagents – working solutions" section for reagents.

Materials required (but not provided)
- 11665064190, Estradiol III CalSet, for 4 x 1 mL
- 11731416190, PreciControl Universal, for 4 x 3 mL
- 11731416160, PreciControl Universal, for 4 x 3 mL (for USA)
- 03609987190, Diluent MultiAssay, 2 x 16 mL sample diluent
- General laboratory equipment
- MODULAR ANALYTICS E170 or cobas e analyzer

Accessories for cobas e 411 analyzer:
- 11662988122, ProCell, 6 x 380 mL system buffer
- 11662970122, CleanCell, 6 x 380 mL measuring cell cleaning solution
- 11930346122, Elecsys Sys Wash, 1 x 500 mL washwater additive
- 11933159001, Adapter for SysClean
- 11706802001, AssayCup, 60 x 60 reaction cups
- 11706799001, AssayTip, 30 x 120 pipette tips
- 11800507001, Clean-Liner

Accessories for MODULAR ANALYTICS E170, cobas e 601 and cobas e 602 analyzers:
- 04880340190, ProCell M, 2 x 2 L system buffer
- 04880293190, CleanCell M, 2 x 2 L measuring cell cleaning solution
- 03023141001, PC/CC-Cups, 12 cups to prewarm ProCell M and CleanCell M before use
- 03005712190, ProbeWash M, 12 x 70 mL cleaning solution for run finalization and rinsing during reagent change
- 03004899190, PreClean M, 5 x 600 mL detection cleaning solution
- 12102137001, AssayTip/AssayCup, 48 magazines x 84 reaction cups or pipette tips, waste bags
- 03023150001, Wasteliner, waste bags
- 03027651001, SysClean Adapter M

Accessories for all analyzers:
- 11298500316, ISE Cleaning Solution/Elecsys SysClean, 5 x 100 mL system cleaning solution
- 11298500160, ISE Cleaning Solution/Elecsys SysClean, 5 x 100 mL system cleaning solution (for USA)

Assay
For optimum performance of the assay follow the directions given in this document for the analyzer concerned. Refer to the appropriate operator’s manual for analyzer-specific assay instructions.

Resuspension of the microparticles takes place automatically prior to use.
Read in the test-specific parameters via the reagent barcode. If in exceptional cases the barcode cannot be read, enter the 15-digit sequence of numbers (except for the cobas e 602 analyzer).

MODULAR ANALYTICS E170, cobas e 601 and cobas e 602 analyzers: PreClean M solution is necessary.
Bring the cooled reagents to approximately 20 °C and place on the reagent disk (20 °C) of the analyzer. Avoid foam formation. The system automatically regulates the temperature of the reagents and the opening/closing of the bottles.

Calibration
Traceability: This method has been standardized against CRM 6004a via ID-
GC/MS (isotope dilution-gas chromatography/mass spectrometry). Every Elecsys reagent set has a barcoded label containing specific information for calibration of the particular reagent lot. The predefined master curve is adapted to the analyzer using the relevant CalSet.

Calibration frequency: Calibration must be performed once per reagent lot using fresh reagent (i.e. not more than 24 hours since the reagent kit was registered on the analyzer). Renewed calibration is recommended as follows:
- after 1 month (28 days) when using the same reagent lot
- after 7 days (when using the same reagent kit on the analyzer)
- as required: e.g. quality control findings outside the defined limits

Quality Control
For quality control, use PreciControl Universal.
In addition, other suitable control material can be used.
Controls for the various concentration ranges should be run individually at least once every 24 hours when the test is in use, once per reagent kit, and following each calibration.
The control intervals and limits should be adapted to each laboratory’s individual requirements. Values obtained should fall within the defined limits. Each laboratory should establish corrective measures to be taken if values fall outside the defined limits.
Follow the applicable government regulations and local guidelines for quality control.

Calculation
The analyzer automatically calculates the analyte concentration of each sample (either in pmol/L, pg/mL, ng/L or additionally in nmol/L with MODULAR ANALYTICS E170, cobas e 601 and cobas e 602 analyzers).

Conversion factors: pmol/L x 0.272 = pg/mL (ng/L)
pg/mL x 3.67 = pmol/L
pg/mL x 0.00367 = nmol/L

Limitations – interference
The assay is unaffected by icterus (bilirubin ≤ 112.9 µmol/L or ≤ 66 mg/dL), hemolysis (Hb ≤ 0.621 mmol/L or ≤ 1.0 g/dL), Ipiemira (Intralipid ≤1000 mg/dL) and biotin (≤ 147 nmol/L or ≤ 36 ng/mL).
Criterion: Recovery within ± 10 % of initial value.
Samples should not be taken from patients receiving therapy with high biotin doses (i.e. > 5 mg/day) until at least 8 hours following the last biotin administration.
No interference was observed from rheumatoid factors up to a concentration of 1200 IU/mL.
In vitro tests were performed on 17 commonly used pharmaceuticals. No interference with the assay was found.
Erroneous test results may be obtained from samples taken from patients who have been exposed to vaccines containing rabbit serum or when keeping rabbits as pet animals.
Due to the risk of cross reactivity, this assay should not be used when monitoring Estradiol levels in patients being treated with Fulvestrant (Faslodex).
Steroid drugs may interfere with this test.
In rare cases, interference due to extremely high titers of antibodies to analyte-specific antibodies, streptavidin or ruthenium can occur. These effects are minimized by suitable test design.
For diagnostic purposes, the results should always be assessed in conjunction with the patient’s medical history, clinical examination and other findings.

Limits and ranges
Measuring range
18.4-11010 pmol/L (5-3000 pg/mL) (defined by the Limit of Detection and the maximum of the master curve). Values below the Limit of Detection are reported as < 18.4 pmol/L or < 5 pg/mL. Values above the measuring range are reported as > 11010 pmol/L or > 3000 pg/mL (or up to 110100 pmol/L or 30000 pg/mL for 10-fold diluted samples)
Lower limits of measurement

<table>
<thead>
<tr>
<th>Limit of Blank, Limit of Detection and Limit of Quantitation</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Limit of Blank = 11 pmol/L (3 pg/mL)</td>
<td></td>
</tr>
<tr>
<td>Limit of Detection = 18.4 pmol/L (5 pg/mL)</td>
<td></td>
</tr>
<tr>
<td>Limit of Quantitation = 91.8 pmol/L (25 pg/mL)</td>
<td></td>
</tr>
</tbody>
</table>

To determine the endogenous analyte concentration of the diluent, a study was performed for Limit of Quantitation using human serum samples diluted and measured in 6 runs over ≥ 3 days on 2 analyzers. At a total allowable error of ≤ 30 %.

The Limit of Blank, Limit of Detection and Limit of Quantitation were determined in accordance with the CLSI (Clinical and Laboratory Standards Institute) EP17-A requirements.

The Limit of Blank is the 95th percentile value from n ≥ 60 measurements of analyte-free samples over several independent series. The Limit of Blank corresponds to the concentration below which analyte-free samples are found with a probability of 95 %.

The Limit of Detection is determined based on the Limit of Blank and the standard deviation of low concentration samples. The Limit of Detection corresponds to the lowest analyte concentration which can be detected (value above the Limit of Blank with a probability of 95 %).

The Limit of Quantitation is defined as the lowest amount of analyte in a sample that can be accurately quantitated with a total allowable error of ≤ 30 %.

Dilution

Samples with estradiol concentrations above the measuring range can be diluted with Diluent MultiAssay. The recommended dilution is 1:10 (automatically by the analyzers). After dilution by the analyzers, the software automatically takes the dilution into account when calculating the sample concentration.

The endogenous analyte concentration of the diluent (< 220 pmol/L or < 60.0 pg/mL) is not taken into account for dilutions above the measuring range.

Expected values

The reference ranges were determined in a Caucasian population.

<table>
<thead>
<tr>
<th>Test subjects</th>
<th>N</th>
<th>2.5th percentile pmol/L (90 % CI)</th>
<th>Median pmol/L (90 % CI)</th>
<th>97.5th percentile pmol/L (90 % CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Healthy men</td>
<td>150</td>
<td>41.4 (22.4-49.0)</td>
<td>90.9 (84.9-97.7)</td>
<td>159 (151-337)</td>
</tr>
<tr>
<td>Healthy women</td>
<td>146</td>
<td>45.4 (22.8-61.2)</td>
<td>196 (183-213)</td>
<td>854 (633-1154)</td>
</tr>
<tr>
<td>Follicular phase</td>
<td>150</td>
<td>151 (105-158)</td>
<td>462 (416-533)</td>
<td>1481 (1162-1925)</td>
</tr>
<tr>
<td>Ovulation phase</td>
<td>151</td>
<td>81.9 (28.2-127)</td>
<td>370 (335-419)</td>
<td>1251 (1077-2759)</td>
</tr>
<tr>
<td>Luteal phase</td>
<td>142</td>
<td>&lt; 18.4 (&lt; 18.4)</td>
<td>&lt; 18.4 (&lt; 18.4)</td>
<td>805 (189-1150)</td>
</tr>
<tr>
<td>Postmenopause</td>
<td>136</td>
<td>584 (467-636)</td>
<td>3132 (2703-4004)</td>
<td>11902 (9891-15271)</td>
</tr>
<tr>
<td>Healthy pregnant women</td>
<td>140</td>
<td>5729 (4173-7457)</td>
<td>28402 (24207-32090)</td>
<td>78938 (69143-92227)</td>
</tr>
<tr>
<td>Postmenopause</td>
<td>136</td>
<td>31287 (27151-34175)</td>
<td>64884 (62353-68189)</td>
<td>&gt; 110100 (107164-111000)</td>
</tr>
</tbody>
</table>

> CI = confidence interval

Each laboratory should investigate the transferability of the expected values to its own patient population and if necessary determine its own reference ranges.

Specific performance data

Representative performance data on the analyzers are given below. Results obtained in individual laboratories may differ.

Precision

Precision was determined using Elecsys reagents, samples and controls in a protocol (EPS-A2) of the CLSI (Clinical and Laboratory Standards Institute): 2 runs per day in duplicate each for 21 days (n = 84). The following results were obtained:

<table>
<thead>
<tr>
<th>Test subjects</th>
<th>N</th>
<th>2.5th percentile pmol/L (90 % CI)</th>
<th>Median pmol/L (90 % CI)</th>
<th>97.5th percentile pmol/L (90 % CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Healthy men</td>
<td>150</td>
<td>11.3 (6.1-13.4)</td>
<td>24.8 (23.1-26.6)</td>
<td>43.2 (41.0-91.9)</td>
</tr>
<tr>
<td>Healthy women</td>
<td>146</td>
<td>12.4 (6.2-16.7)</td>
<td>53.4 (49.0-58.1)</td>
<td>233 (173-315)</td>
</tr>
<tr>
<td>Follicular phase</td>
<td>150</td>
<td>41.0 (28.6-43.2)</td>
<td>126 (113-145)</td>
<td>396 (317-525)</td>
</tr>
<tr>
<td>Ovulation phase</td>
<td>151</td>
<td>22.3 (7.69-34.6)</td>
<td>101 (91.2-114)</td>
<td>341 (294-752)</td>
</tr>
<tr>
<td>Luteal phase</td>
<td>142</td>
<td>&lt; 5 (&lt; 5)</td>
<td>&lt; 5 (&lt; 5)</td>
<td>138 (51.6-314)</td>
</tr>
<tr>
<td>Postmenopause</td>
<td>136</td>
<td>154 (127-173)</td>
<td>854 (737-1091)</td>
<td>3243 (2695-4161)</td>
</tr>
<tr>
<td>Follicular phase</td>
<td>140</td>
<td>1561 (1137-2032)</td>
<td>7739 (6596-8744)</td>
<td>21280 (18840-25130)</td>
</tr>
<tr>
<td>Ovulation phase</td>
<td>136</td>
<td>8525 (7398-9312)</td>
<td>17625 (16900-18580)</td>
<td>&gt; 30000 (29200-30000)</td>
</tr>
</tbody>
</table>

cobas e 411 analyzers

<table>
<thead>
<tr>
<th>Test subjects</th>
<th>N</th>
<th>Mean pmol/L</th>
<th>SD pmol/L</th>
<th>CV %</th>
<th>Mean pmol/L</th>
<th>SD pmol/L</th>
<th>CV %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sample</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Human serum 1</td>
<td>93.3</td>
<td>7.91</td>
<td>8.5</td>
<td>11.1</td>
<td>11.9</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Human serum 2</td>
<td>166</td>
<td>7.75</td>
<td>4.7</td>
<td>11.4</td>
<td>6.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Human serum 3</td>
<td>605</td>
<td>18.8</td>
<td>3.1</td>
<td>20.4</td>
<td>3.4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Human serum 4</td>
<td>5021</td>
<td>97.7</td>
<td>1.9</td>
<td>125</td>
<td>2.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Human serum 5</td>
<td>10760</td>
<td>253</td>
<td>2.4</td>
<td>297</td>
<td>2.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PC U11</td>
<td>316</td>
<td>11.0</td>
<td>3.5</td>
<td>14.1</td>
<td>4.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PC U2</td>
<td>1514</td>
<td>47.8</td>
<td>3.2</td>
<td>53.7</td>
<td>3.5</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

cobas e 610 and cobas e 602 analyzers

<table>
<thead>
<tr>
<th>Test subjects</th>
<th>N</th>
<th>Mean pmol/L</th>
<th>SD pmol/L</th>
<th>CV %</th>
<th>Mean pmol/L</th>
<th>SD pmol/L</th>
<th>CV %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sample</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Human serum 1</td>
<td>101</td>
<td>6.79</td>
<td>6.7</td>
<td>10.6</td>
<td>10.6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Human serum 2</td>
<td>173</td>
<td>6.46</td>
<td>3.7</td>
<td>9.8</td>
<td>5.7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Human serum 3</td>
<td>584</td>
<td>9.62</td>
<td>1.6</td>
<td>14.4</td>
<td>2.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Human serum 4</td>
<td>4661</td>
<td>53.2</td>
<td>1.1</td>
<td>86.2</td>
<td>1.9</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Human serum 5</td>
<td>9982</td>
<td>189</td>
<td>1.9</td>
<td>296</td>
<td>3.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PC U1</td>
<td>329</td>
<td>7.82</td>
<td>2.4</td>
<td>12.4</td>
<td>3.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PC U2</td>
<td>1497</td>
<td>18.0</td>
<td>1.2</td>
<td>30.8</td>
<td>2.1</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

cobas e 610 and cobas e 602 analyzers

<table>
<thead>
<tr>
<th>MODULAR ANALYTICS E170, cobas e 610 and cobas e 602 analyzers</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Repeatability</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intermediate precision</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

2016-11, V 4.0 Can English
### Estradiol III

##### cobas e 411 analyzers

<table>
<thead>
<tr>
<th>Sample</th>
<th>Mean (pg/mL)</th>
<th>SD (pg/mL)</th>
<th>CV (%)</th>
<th>SD (pg/mL)</th>
<th>CV (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1257</td>
<td>1.26</td>
<td>0.19</td>
<td>15.0</td>
<td>0.20</td>
<td>16.3</td>
</tr>
<tr>
<td>254</td>
<td>2.16</td>
<td>0.19</td>
<td>9.3</td>
<td>0.20</td>
<td>9.5</td>
</tr>
<tr>
<td>513</td>
<td>3.23</td>
<td>0.22</td>
<td>7.0</td>
<td>0.24</td>
<td>7.5</td>
</tr>
<tr>
<td>946</td>
<td>3.23</td>
<td>0.22</td>
<td>7.0</td>
<td>0.24</td>
<td>7.5</td>
</tr>
<tr>
<td>1258</td>
<td>3.23</td>
<td>0.22</td>
<td>7.0</td>
<td>0.24</td>
<td>7.5</td>
</tr>
<tr>
<td>162</td>
<td>3.23</td>
<td>0.22</td>
<td>7.0</td>
<td>0.24</td>
<td>7.5</td>
</tr>
<tr>
<td>184</td>
<td>3.23</td>
<td>0.22</td>
<td>7.0</td>
<td>0.24</td>
<td>7.5</td>
</tr>
<tr>
<td>225</td>
<td>3.23</td>
<td>0.22</td>
<td>7.0</td>
<td>0.24</td>
<td>7.5</td>
</tr>
<tr>
<td>264</td>
<td>3.23</td>
<td>0.22</td>
<td>7.0</td>
<td>0.24</td>
<td>7.5</td>
</tr>
<tr>
<td>305</td>
<td>3.23</td>
<td>0.22</td>
<td>7.0</td>
<td>0.24</td>
<td>7.5</td>
</tr>
</tbody>
</table>

##### MODULAR ANALYTICS E170, cobas e 601 and cobas e 602 analyzers

<table>
<thead>
<tr>
<th>Sample</th>
<th>Mean (pg/mL)</th>
<th>SD (pg/mL)</th>
<th>CV (%)</th>
<th>SD (pg/mL)</th>
<th>CV (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1257</td>
<td>1.26</td>
<td>0.19</td>
<td>15.0</td>
<td>0.20</td>
<td>16.3</td>
</tr>
<tr>
<td>254</td>
<td>2.16</td>
<td>0.19</td>
<td>9.3</td>
<td>0.20</td>
<td>9.5</td>
</tr>
<tr>
<td>513</td>
<td>3.23</td>
<td>0.22</td>
<td>7.0</td>
<td>0.24</td>
<td>7.5</td>
</tr>
<tr>
<td>946</td>
<td>3.23</td>
<td>0.22</td>
<td>7.0</td>
<td>0.24</td>
<td>7.5</td>
</tr>
<tr>
<td>1258</td>
<td>3.23</td>
<td>0.22</td>
<td>7.0</td>
<td>0.24</td>
<td>7.5</td>
</tr>
<tr>
<td>162</td>
<td>3.23</td>
<td>0.22</td>
<td>7.0</td>
<td>0.24</td>
<td>7.5</td>
</tr>
<tr>
<td>184</td>
<td>3.23</td>
<td>0.22</td>
<td>7.0</td>
<td>0.24</td>
<td>7.5</td>
</tr>
<tr>
<td>225</td>
<td>3.23</td>
<td>0.22</td>
<td>7.0</td>
<td>0.24</td>
<td>7.5</td>
</tr>
<tr>
<td>264</td>
<td>3.23</td>
<td>0.22</td>
<td>7.0</td>
<td>0.24</td>
<td>7.5</td>
</tr>
<tr>
<td>305</td>
<td>3.23</td>
<td>0.22</td>
<td>7.0</td>
<td>0.24</td>
<td>7.5</td>
</tr>
</tbody>
</table>

#### Method comparison

A comparison of the Elecsys Estradiol III assay (y) with ID-GC/MS (x) using clinical samples gave the following correlations (pg/mL):

- Number of samples measured: 25
- Passing/Bablok analysis: Linear regression
  - \( y = 0.993x + 1.26 \)
  - \( r = 0.987 \)
- The sample concentrations were between 37.4 and 10768 pg/mL (ID-GC-MS concentrations).

#### Analytical specificity

For the Estradiol III assay, the following cross-reactivities were found (in %):

- a) Substance added in a concentration of 0.001 µg/mL:
  - 6-alpha-Hydroxy-Estradiol: 74.1

- b) Substance added in a concentration of 0.01 µg/mL:
  - 4-Hydroxyestriadiol: 0.754

- c) Substance added in a concentration of 0.1 µg/mL:
  - Aldosterone: 0.005
  - Androstenedione: 0.005
  - Equilin: 0.057
  - Estriol: 0.233
  - Estrone: 0.757
  - Estrone-3-glucuronide: 0.003
  - Estrone-3-sulfate: 0.002
  - Ethisterone: 0.002
  - Norethindrone acetate: n.d.

- d) Substance added in a concentration of 0.2 µg/mL:
  - 17-α-Ethinyleradiol: 0.334
  - Cortisol: 0.003
  - Cortisone: 0.001
  - Tamoxifen: 0.001

- e) Substance added in a concentration of 0.25 µg/mL:
  - Chlormephine: 0.001

- f) Substance added in a concentration of 1.0 µg/mL:
  - Prednisolone: n. d.

- g) Substance added in a concentration of 10 µg/mL:
  - Danazol: 0.001
  - DHEA-S: n. d.
  - Mesterolone: n. d.
  - Testosterone: n. d.
  - 5-α-Dihydrotestosterone (DHT): n. d.
  - 5-Androstene-3ß-, 17ß-diol: n. d.

#### References


For further information, please refer to the appropriate operator's manual for the analyzer concerned, the respective application sheets, the product information and the Method Sheets of all necessary components (if available in your country).

A point (period/stop) is always used in this Method Sheet as the decimal separator to mark the border between the integral and the fractional parts of a decimal numeral. Separators for thousands are not used.
Symbols
Roche Diagnostics uses the following symbols and signs in addition to those listed in the ISO 15223-1 standard:

- **CONTENT**: Contents of kit
- **SYSTEM**: Analyzers/Instruments on which reagents can be used
- **REAGENT**: Reagent
- **CALIBRATOR**: Calibrator
- **GTRN**: Volume after reconstitution or mixing
- **GTIN**: Global Trade Item Number

FOR US CUSTOMERS ONLY: LIMITED WARRANTY

Roche Diagnostics warrants that this product will meet the specifications stated in the labeling when used in accordance with such labeling and will be free from defects in material and workmanship until the expiration date printed on the label. THIS LIMITED WARRANTY IS IN LIEU OF ANY OTHER WARRANTY, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR PARTICULAR PURPOSE. IN NO EVENT SHALL ROCHE DIAGNOSTICS BE LIABLE FOR INCIDENTAL, INDIRECT, SPECIAL OR CONSEQUENTIAL DAMAGES.

COBAS, COBAS E, ELECSYS and PRECICONTROL are trademarks of Roche. INTRALIPID is a trademark of Fresenius Kabi AB.

All other product names and trademarks are the property of their respective owners.

Additions, deletions or changes are indicated by a change bar in the margin.

© 2016, Roche Diagnostics

Roche Diagnostics GmbH, Sandhofer Straße 116, D-68305 Mannheim
www.roche.com

Distribution in USA by:
Roche Diagnostics, Indianapolis, IN
US Customer Technical Support 1-800-428-2306